Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease

BACKGROUND/AIMS: The current treatment for anemia associated with chronic kidney disease (CKD) includes the administration of erythropoiesis stimulating agents (ESAs) combined with iron supplementation. Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has potential to treat anemi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Nephron Clin Pract
Главные авторы: Akizawa, Tadao, Macdougall, Iain C., Berns, Jeffrey S., Yamamoto, Hiroyasu, Taguchi, Megumi, Iekushi, Kazuma, Bernhardt, Thomas
Формат: Artigo
Язык:Inglês
Опубликовано: S. Karger AG 2019
Предметы:
Clinical Practice: Original Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6979436/
https://ncbi.nlm.nih.gov/pubmed/31387097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000502012
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы